AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1897688
Drug: L-648,051 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-648,051 (800 micrograms) inhaled before antigen challenge (5 min before)
Trial: 28542611
Drug: ZIKV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZIKV testing (plasma samples for ZIKV nucleic acid and antibodies)
Trial: 24825530
Drug: Dexamethasone 40
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg (D40)
Trial: 24825530
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg (D8)
Trial: 17440005
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (deactivation of ICD therapies for AT/AF)
Trial: 20637970
Drug: Avanafil 100
RxNorm normalized name: avanafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil 100 mg
Trial: 26037035
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) bolus infusion of insulin aspart (NovoRapid U-100)
Trial: 20920848
Drug: Three-times daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times daily tobramycin and ceftazidime
Trial: 19100416
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii (T II) 1 mg/kg/d for 12 months
Trial: 8793604
Drug: Pantoprazole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 30 mg i.v. (acute study)
Trial: 6432172
Drug: Omeprazole 30
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 30 mg
Trial: 15109187
Drug: Omeprazole 60
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 60 mg
Trial: 20105039
Drug: Combination (C)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (C) wave
Trial: 20105039
Drug: Modified Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Combination (MC) wave
Trial: 17622884
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (400 mg loading dose followed by 200 mg QD for one week)
Trial: 11995262
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 or 10 mg according to age)
Trial: 12053590
Drug: Nedocromil (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil (16 mg)
Trial: 2196121
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (aminoglycoside, amoxicillin, clindamycin)
Trial: 372823
Drug: Poly I:C
RxNorm normalized name: poly I:C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly I:C immunotherapy
Trial: 26188923
Drug: Vascular medicine
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular medicine physicians (VMP) managing iDDVT
Trial: 26188923
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of iDDVT as long as proximal DVT by GP
Trial: 26188923
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of iDDVT by VMP
Trial: 16358612
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment protocol for heart failure patients in general practice, based on many RCT's and reviews.
Trial: 16358612
Drug: Co- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co- and multi-medication in frail elderly patients.
Trial: 753026
Drug: Estramustine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estramustine and prednimustine combination
Trial: 24158326
Drug: Electrostimulator (ES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulator (ES) technique with 0.2 ml/kg (E1)
Trial: 24158326
Drug: Electrostimulator (ES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulator (ES) technique with 0.6 ml/kg (E2)
Trial: 24158326
Drug: Electrostimulator (ES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulator (ES) technique with 1.0 ml/kg (E3)
Trial: 24158326
Drug: Blinded technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded technique with 1.0 ml/kg (B4)
Trial: 21707914
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without cell therapy
Trial: 19012356
Drug: Celecoxib 3
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 3 mg/kg bid
Trial: 19012356
Drug: Celecoxib 6
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 6 mg/kg bid
Trial: 19012356
Drug: Naproxen 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 7.5 mg/kg bid
Trial: 29766891
Drug: Continuous heparin
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous heparin infusion
Trial: 11554015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heparin infusion)
Trial: 8148280
Drug: 5.0 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg/day CyA
Trial: 8148280
Drug: 2.5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day CyA
Trial: 8148280
Drug: CyA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA (both doses)
Trial: 30044938
Drug: BCX7353 125
RxNorm normalized name: BCX7353
DrugBank: Berotralstat (DB15982)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCX7353 125 mg
Trial: 23748750
Drug: Ticagrelor 400
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 400 mg qd
Trial: 23748750
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg bid on day 6 and 0.25 mg qd on days 7-14)
Trial: 23748750
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and digoxin co-administration
Trial: 19099634
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose thalidomide (HD-T)
Trial: 19099634
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose thalidomide (LD-T)
Trial: 19099634
Drug: Conventional VAD
RxNorm normalized name: VAD-044
DrugBank: VAD-044 (DB17697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional VAD chemotherapy
Trial: 9595974
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg daily for 2 consecutive days every month for 6 months
Trial: 8015122
Drug: Concealment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concealment of assignment until treatment allocation
Trial: 2853751
Drug: Yohimbine infusion
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine infusion (3 micrograms/kg per min) during glucose infusion (20 min) in group I
Trial: 27943089
Drug: Diltiazem co-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem co-treatment with microemulsified cyclosporine-A (CsA)
Trial: 21167116
Drug: Trivalent seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent seasonal influenza vaccine
Trial: 22472791
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg antigen with a full (9.75 mg) adjuvant dose
Trial: 22472791
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg antigen with a half (4.875 mg) adjuvant dose
Trial: 18258801
Drug: Hypoglycemia (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (mean nadir plasma glucose 2.7 +/- 0.5 mmol/l)
Trial: 15930210
Drug: Dopamine (DP)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DP) at doses of 2.5, 5, 7.5, or 10 microg/kg per minute; n = 28
Trial: 15930210
Drug: Epinephrine (EP)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EP) at doses of 0.125, 0.250, 0.375, or 0.5 microg/kg per minute; n = 32
Trial: 8894955
Drug: Brief cognitive-behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive-behaviour therapy (CBT)
Trial: 31662354
Drug: Marketing authorisation
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketing authorisation withdrawal or suspension
Trial: 29578578
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg every 4 weeks
Trial: 19384220
Drug: Daily bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bathing with chlorhexidine solution
Trial: 15345983
Drug: Less Invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less Invasive Stabilization System (L.I.S.S.) plating
Trial: 15345983
Drug: L.I.S.S plate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L.I.S.S plate
Trial: 18697778
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for lower TJC patients
Trial: 18697778
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for higher TJC patients
Trial: 18697778
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for lower SJC patients
Trial: 18697778
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for higher SJC patients
Trial: 16860176
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine 35 microg/h
Trial: 9102740
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 2 weeks
Trial: 31055857
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (1 g/kg body weight)
Trial: 12681528
Drug: GHB (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (50 mg/kg t.i.d for 3 months)
Trial: 8824652
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine b.d.
Trial: 1358235
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine q.d.s.
Trial: 2491468
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine nocte
Trial: 3714083
Drug: Thyropramide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyropramide (300 mg per diem for 3 days per os)
Trial: 23275364
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (4 g/day)
Trial: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) 3 mg
Trial: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 8 mg + Glimepiride (GLIM) 3 mg
Trial: 18201206
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) + Glimepiride (GLIM) 3 mg
Trial: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) (low-dose prior to uptitration)
Trial: 18201206
Drug: Glimepiride (GLIM)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride (GLIM) monotherapy
Trial: 21324094
Drug: Gepirone-ER (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone-ER (20-80 mg/day)
Trial: 11487258
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg o.d.)
Trial: 11487258
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg o.d.)
Trial: 11487258
Drug: Anastrozole and
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole and Tamoxifen (1 mg and 20 mg o.d. respectively)
Trial: 16463847
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) administration
Trial: 3140862
Drug: nalmefene 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalmefene 0.4 mg/70 kg
Trial: 30157896
Drug: 3 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 monthly ART supply through community ART groups (CAGs)
Trial: 30157896
Drug: 6 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 monthly ART supply through community ART distribution points (CAD)
Trial: 20618595
Drug: Stretching exercise
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching exercise (daily from 18 weeks of gestation to the end of pregnancy)
Trial: 14645935
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patches
Trial: 7468948
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulphate aerosol via a 10 cm tube extension
Trial: 7468948
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg salbutamol sulphate via conventional pressurized aerosol
Trial: 25989606
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day memantine (MMT+M)
Trial: 24604528
Drug: Fit2Quit intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fit2Quit intervention (10 exercise telephone counseling sessions over 6 months) plus usual care (behavioral counseling and nicotine replacement therapy)
Trial: 21121983
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg/day
Trial: 12375667
Drug: G-CSF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (3 microg/kg) plus dexamethasone (8 mg orally)
Trial: 12375667
Drug: G-CSF (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (12 microg/kg) alone
Trial: 12622856
Drug: Braun Oral-B
RxNorm normalized name: bran Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral-B 3D Plaque Remover
Trial: 29862269
Drug: Conventional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implants
Trial: 25479585
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate 20 mg in 500 mL of 5% glucose solution
Trial: 25479585
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (500 mL of 5% glucose solution)
Trial: 2654259
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg daily (N = 37)
Trial: 25488124
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2.0 mg)
Trial: 15489091
Drug: Renal insufficiency
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal insufficiency categorized as creatinine clearance (CrCl) <40 ml/min
Trial: 15489091
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (users)
Trial: 15489091
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (nonusers)
Trial: 2876723
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg levocabastine
Trial: 2876723
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg disodium cromoglycate (DSCG)
Trial: 2786751
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg daily)
Trial: 2786751
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg and 50 micrograms/kg)
Trial: 2786751
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg)
Trial: 25470888
Drug: Lidocaine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (group L)
Trial: 28914415
Drug: Warfarin maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin maintenance doses
Trial: 28914415
Drug: Warfarin loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin loading doses
Trial: 30265586
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal (SW)
Trial: 23429258
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal (SW) in prepubertal patients
Trial: 17145137
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg T enanthate
Trial: 11833925
Drug: Incredible Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incredible Years Parenting Program (8-12 weeks of weekly 2-hour parenting classes)
Trial: 9727892
Drug: T600/G12 (troglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T600/G12 (troglitazone 600 mg + glyburide 12 mg)
Trial: 11271239
Drug: FK 506
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 506 therapy
Trial: 11271239
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A therapy
Trial: 28330586
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=6)
Trial: 26060625
Drug: Levonorgestrel 0.75
RxNorm normalized name: levonorgestrel 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 0.75 mg given 12 hours apart
Trial: 26060625
Drug: Yuzpe regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuzpe regimen (ethinyl estradiol 100 μg plus 0.5 mg Levonorgestrel repeated after 12 hours)
Trial: 21705296
Drug: Palpation by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation by a sports medicine board‐certified staff physician
Trial: 20055196
Drug: Drug-free group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free group (Control)
Trial: 16960118
Drug: Synthetic oligosaccharide-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic oligosaccharide-protein conjugate vaccine, administered as a single intramuscular injection.
Trial: 9586883
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: MTX 1,000 mg/m2 i.v. infused over 24 hours and MP 1,000 mg/m2 i.v. infused over 6 hours
Trial: 9586883
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: Low-dose repetitive MTX 30 mg/m2 orally every 6 hours for six doses and i.v. MP
Trial: 3280257
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg po, qid for three extra days (Group A)
Trial: 3280257
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral therapy (Group B)
Trial: 26016586
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education video game
Trial: 9484875
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg tds